These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18428198)

  • 1. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
    Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
    Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
    Beer TM
    BJU Int; 2005 Sep; 96(4):508-13. PubMed ID: 16104901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Redfern CH; Fehrenbacher L; Saleh MN; Waterhouse DM; Carducci MA; Vicario D; Dreicer R; Higano CS; Ahmann FR; Chi KN; Henner WD; Arroyo A; Clow FW;
    J Clin Oncol; 2007 Feb; 25(6):669-74. PubMed ID: 17308271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
    Daskivich TJ; Regan MM; Oh WK
    Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Chi KN; Young J; Henner WD;
    Cancer; 2008 Jan; 112(2):326-30. PubMed ID: 17960793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
    Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
    BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
    J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
    Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
    Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
    Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
    Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer.
    McArdle PA; Mir K; Almushatat AS; Wallace AM; Underwood MA; McMillan DC
    Urol Int; 2006; 77(2):127-9. PubMed ID: 16888416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
    BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.
    Ito M; Saito K; Yasuda Y; Sukegawa G; Kubo Y; Numao N; Kitsukawa S; Urakami S; Yuasa T; Yamamoto S; Yonese J; Fukui I
    Urology; 2011 Nov; 78(5):1131-5. PubMed ID: 22054387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
    Svatek R; Karakiewicz PI; Shulman M; Karam J; Perrotte P; Benaim E
    Eur Urol; 2006 Apr; 49(4):666-74. PubMed ID: 16423446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.